A Study of PTR-01 in Recessive Dystrophic Epidermolysis Bullosa

Phase 2 Completed 6 enrolled Phoenix Tissue Repair, Inc.

NaSingle-groupOpen-labelTreatment

Summary

Protocol PTR-01-002 is a 3-part Phase 2, open-label study of PTR-01. While new patients will be enrolled, priority will be given to patients that satisfactorily completed study PTR-01-001.

Timeline

Start: 2020-10-15
Primary completion: 2021-08-28
Completion: 2021-09-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	PTR-01	Protein / enzyme biologic	3 mg/kg	Intravenous

A Study of PTR-01 in Recessive Dystrophic Epidermolysis Bullosa

Summary

Timeline

Drugs

Indications